UK Markets closed

Roche Holding AG (ROG.SW)

Swiss - Swiss Delayed price. Currency in CHF
Add to watchlist
354.55-3.40 (-0.95%)
At close: 5:31PM CEST

Roche Holding AG

Konzern Hauptsitz
Grenzacherstrasse 124
Basel 4070
41 61 688 11 11

IndustryDrug Manufacturers—General
Full-time employees101,465

Key executives

NameTitlePayExercisedYear born
Dr. Severin SchwanCEO & Exec. Director7.06MN/A1967
Dr. Alan HippeChief Financial & Information Officer4.02MN/A1967
Ms. Cristina A. WilburChief People Officer2.65MN/A1967
Mr. Thomas SchineckerChief Exec. Officer of Roche Diagnostics2.57MN/A1975
Mr. William N. AndersonChief Exec. Officer of Roche Pharmaceuticals5.66MN/A1966
Dr. Karl MahlerHead of Investor RelationsN/AN/AN/A
Ms. Claudia BoeckstiegelGen. CounselN/AN/A1964
Ms. Pascale SchmidtChief Compliance OfficerN/AN/A1973
Mr. Nicolas DunantHead of Group Media RelationsN/AN/AN/A
Ehab YousefHead of Middle East Sub-Region 1N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.


Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Corporate governance

Roche Holding AG’s ISS governance QualityScore as of 1 June 2021 is 8. The pillar scores are Audit: 10; Board: 4; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.